Please assess the completion status of the following clinical trial:

Trial Title: Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants in good health~Exclusion Criteria:~* Previous administration of any oral poliovirus vaccine (OPV) and rotavirus vaccine~* Receipt of inactivated poliovirus vaccine (IPV) prior to the first dose of either study vaccine, or at any time during the course of the study~* Any condition resulting in depressed immunity~* Any allergy to any vaccine component as stated in the package circulars~* Allergies to polymyxin B, neomycin or any other antibiotics~* Receipt of intramuscular, oral, or intravenous corticosteroid treatment~* History of congenital abdominal disorders, intussusception, or abdominal surgery; clinical evidence of active gastrointestinal illness~* History of known prior rotavirus gastroenteritis, chronic diarrhea, or failure to thrive~* Prior receipt of a blood transfusion or blood products, including immunoglobulin~* Fever, with a rectal temperature of ≥38.1°C (≥ 100.5°F) at the time of immunization~* Infants residing in a household with an immunocompromised person

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq and OPV concomitantly
- 2 (Type: EXPERIMENTAL): RotaTeq and OPV on staggered schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).